Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Research output: Contribution to journalArticle

Abstract

Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially disabling motor complications. Experimental studies suggest that motor complications are due to non-physiological, intermittent administration of the drug, and can be reduced with continuous delivery. We aimed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through an intrajejunal percutaneous tube.

Details

Authors
  • C Warren Olanow
  • Karl Kieburtz
  • Per Odin
  • Alberto J Espay
  • David G Standaert
  • Hubert H Fernandez
  • Arvydas Vanagunas
  • Ahmed A Othman
  • Katherine L Widnell
  • Weining Z Robieson
  • Yili Pritchett
  • Krai Chatamra
  • Janet Benesh
  • Robert A Lenz
  • Angelo Antonini
  • LCIG Horizon Study Group
Organisations
External organisations
  • Skåne University Hospital
  • Central Hospital Bremerhaven
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology
Original languageEnglish
Pages (from-to)141-149
JournalLancet Neurology
Volume13
Issue number2
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes